Key takeaway: The investor presentation for Akums Drugs and Pharmaceuticals Limited reported on the company's performance for Q4 and FY26, highlighting a strong finish despite challenges in the first half of the fiscal year. Management noted that the operating environment was difficult, marked by declining API prices and low growth in the domestic market. However, they emphasized strong operational performance in the second half, particularly in the CDMO business, which contributed to improved gross margins through cost optimization. Key growth drivers outlined included sustained momentum in the domestic CDMO sector, expansion into international markets, and the commissioning of a facility in Zambia. Financial highlights showed a total income of INR 1,050 crore for Q4 FY26, with an adjusted EBITDA of INR 121 crore. The presentation also detailed the company's strategic focus on innovation and operational efficiency, alongside a commitment to long-term shareholder value.

Key takeaway: During the earnings call for Q3 FY26, management reported a strong quarter characterized by healthy operating performance and significant growth in the CDMO segment, which saw over 16% top-line growth driven by strong volumes. The international branded formulation business improved due to demand recovery, while domestic branded formulations continued to grow steadily. Management noted that API pricing remained under pressure but highlighted efforts to mitigate impacts on margins through disciplined cost management. The company advanced on regulatory milestones for its European CDMO project and reported progress on the Zambia project. Financial highlights included a 14.8% year-on-year increase in operating revenue to INR 1,160 crores and a 21% year-on-year increase in EBITDA. Management emphasized a focus on long-term growth drivers, including innovation and operational efficiency, while reiterating their commitment to creating long-term value for shareholders.

Key takeaway: The investor presentation from Akums Drugs and Pharmaceuticals Limited reported strong performance for Q3 FY26, highlighting a 16% growth in the CDMO segment driven by increased volumes. The international branded formulation business showed significant improvement due to demand recovery in key markets. Management noted that while API pricing remained under pressure, cost management strategies helped mitigate impacts on margins. The presentation detailed progress on the European CDMO project, including the receipt of EUGMP certification and the commencement of supplies to Europe. The API segment faced challenges, but ongoing portfolio rationalization and cost optimization efforts were noted to have contained losses. Overall, management emphasized a commitment to long-term growth through innovation and operational efficiency, while acknowledging the volatile business environment. Financial highlights included a total income of INR 1,160 crore for Q3 FY26, reflecting a 14.8% year-over-year increase, and an adjusted PAT of INR 68 crore, up 2.1% year-over-year.